The 27th “Stock Exchange Company of the Year” gala, a competition organized by the editorial team of Puls Biznesu, is now behind us. Each year, the selection of the best of the best is made by 100 stock market analysts, investment advisors, and asset managers representing brokerage houses and offices, pension funds, and investment funds. In the latest edition of the poll, we received the highest scores in the “Growth Prospects” category. We placed third in the categories “Highest Innovation in Products and Services” and “Investor Relations.” In the overall ranking, we are once again in the TOP3.
In its latest article, Puls Biznesu reminds readers that we are on the final straight before registering our first drug on the EU market.
“Bioceltix is on the podium for the second consecutive time, standing out among publicly listed biotech companies because it develops drugs not for humans, but for animals. And this makes it significantly faster,” we read in the article by editor Marcel Zatoński.
“Bioceltix stands out among biotechnology companies listed on the WSE in terms of the advancement of its work, as applications have already been submitted for the registration of two drug candidates—one for osteoarthritis in dogs and another for arthritis in horses. In the case of registration for dogs, an extension of indications to include atopic dermatitis is also planned. Of course, in veterinary biotechnology, reaching this stage is less complex than in the case of drugs intended for humans, but clinical trial data provide a strong proof of concept for the company’s portfolio projects,” comments Beata Szparaga-Waśniewska, analyst at mBank Brokerage Office.
We encourage you to read the full article (available in Polish): https://www.pb.pl/gieldowa-spolka-roku-2025-bioceltix-w-blokach-startowych-po-lekowe-miliony-1258779